Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

CGRP Antibodies as Prophylaxis in Migraine

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The Polygenic and Monogenic Basis of Blood Traits and Diseases

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Trans-ethnic and Ancestry-Specific Blood-Cell Genetics in 746,667 Individuals from 5 Global Populations

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Human Disease Variation in the Light of Population Genomics

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Vancouver Declaration II on Global Headache Patient Advocacy 2019

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Expression of the CGRP Family of Neuropeptides and their Receptors in the Trigeminal Ganglion

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (CLR + RAMP1) offer considerable improvements over existing drugs in migraine prophylaxis and are the first designed to act on the trigeminal pain system. Erenumab is approved by the FDA and EMA and has reached the market since May 2018. Two antibodies, fremanezumab and galcanezumab, directed towards the CGRP ligand, were approved by the FDA in September 2018. To view this Bench to Bedside, open or download the PDF.

OriginalsprogEngelsk
TidsskriftCell
Vol/bind175
Udgave nummer7
Sider (fra-til)1719
ISSN0092-8674
DOI
StatusUdgivet - 2018
Eksternt udgivetJa

ID: 55839281